Caligan Partners’s Eledon Pharmaceuticals ELDN Stock Holding History

Caligan Partners’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-555,978	Closed	-$840K	–	29
2025 Q4	$840K	Buy	+555,978	New	+$1.32M	0.07%	24

Other funds holding ELDN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $712M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Caligan Partners's ELDN Position: Q1 2026 in Review

Caligan Partners sold out of Eledon Pharmaceuticals (ELDN) in Q1 2026, closing a stake of 555,978 shares — an estimated $840K sold.

Caligan Partners first reported a position in ELDN in Q4 2025 and held it in 1 quarter. The position peaked at $840K in Q4 2025. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

Caligan Partners reported no remaining Eledon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Caligan Partners sold 555,978 Eledon Pharmaceuticals shares in Q1 2026, an estimated $840K.
Caligan Partners first reported a position in Eledon Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Caligan Partners's Eledon Pharmaceuticals position peaked at $840K in Q4 2025.
121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Caligan Partners's 13F filing for Q1 2026, filed 15 May 2026.